Regulatory approval first Sono-Coat™ product
In July 2020 our undisclosed top-10 MedTech customer obtained FDA approval for a MW ablation needle with a Sono-Coat™ tip.
Standard medical devices have a poor visibility in ultrasound imaging, creating a risk when carrying out medical interventions
Mediocre needle visibility leads to multiple insertion and repositioning efforts causing patient discomfort and an increased failure rate in vascular access and biopsy procedures
Sono-Coat™ is a game-changing technology in situations “when precision counts”. Sono-Coat™ catheters and needles are clearly visible in the image, allowing effortless location from any possible angle
The use of Sono-Coat™ devices leads to an accurate diagnosis, reduced complication rates and better patient outcomes
Sono-Coat™ provides excellent ultrasound visibility for catheters and needles, supporting clinicians in safely and accurately performing US-guided procedures
In deeper tissue structures the Sono-Coat™ technology
enables precise targeting of objects
Patients benefit from safe, quick and first-time-right interventions
The Sono-Coat™ technology is based on a coating matrix containing acoustically reflective microspheres. The reflective microspheres scatter the ultrasound waves in all directions
This scattering effect causes more ultrasound signal to be reflected to the probe, no matter the angle, resulting in a clear, sharp image on the screen
The NICE study published in GIE compares the ultrasound visibility of a Sono-Coat™ needle and 8 commonly used echogenic needles. The Sono-Coat™ needle outperformed (p<0.01) all other echogenic needles and was ranked number 1 in ultrasound visibility during a blind review by 60 interventional clinicians
The Sono-Coat technology can be applied to a large variety of medical devices: the P-series coating system specifically developed for Polyurethane, Nylon, PEBAX, PEEK, PVC, and Polysilicon devices and the M-Series for Steel, Titanium, Nitinol and Ceramic based devices
Sono-Coat™ is biocompatible, temperature resistant, and can be overcoated with lubricious, anti-microbial and anti-thrombogenic coatings without loss of echogenicity
Heico Breek is responsible for overall management of the company, strategy and business development, strategic alliances, funding and investor relations. Before joining Encapson, Heico held senior management positions in Europe and the United States at Aventis Pharma as Vice-President Global Marketing. He was General Manager of Aventis AB in Sweden. After moving to biotech he was Chief Commercial Officer at Tigenix NV, Belgium. Heico holds a Medical Degree from VU University Amsterdam and an Executive MBA from Erasmus University Rotterdam.
Lee Ayres is co-founder of Encapson and led the development of the Sono-Coat™ technology. Lee is responsible for the improvement and upscaling of Encapson’s coating technology platforms, managing customer sample tracks, business development and introducing technical innovations. Lee has built an extensive industry network focused on developing echogenic solutions for medical devices. Lee holds a Master's Degree in Chemistry from University of York and a PhD from the Radboud University of Nijmegen in Synthetic Polymer Chemistry.
Bram Pape leads the operational organization and is responsible for running Encapson’s day-to-day business and implements standardized business processes. He has a background in Project Management and R&D in the pharmaceuticaland medical industry at FeyeCon Carbon Dioxide Technologies, Océ Technologies and TMC. Bram holds a Master’s degree in Chemistry from Radboud University in Nijmegen and a PhD from the Eindhoven University of Technology in development of biomaterials for Regenerative Medicine and Drug Delivery.
In July 2020 our undisclosed top-10 MedTech customer obtained FDA approval for a MW ablation needle with a Sono-Coat™ tip.
Munich, Germany – May 29-31, 2021
Lisbon, Portugal – September 25-29, 2021
Online - March 20-26, 2021
